Science China. Life sciencesOct 11, 2026

Inflammation as a key factor in the development and treatment resistance of acute myeloid leukemia

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 13, 2026

Abstract

Inflammation in the bone marrow microenvironment is associated with acute myeloid leukemia progression and therapeutic resistance.

Inflammatory signals in acute myeloid leukemia may arise from various sources, including age-related inflammation and mutation-driven pathways.
These inflammatory signals could facilitate the progression from pre-leukemic states to overt leukemia and support malignant cell growth.
An inflammatory niche is established by leukemic cells and other components of the bone marrow, producing cytokines and chemokines.
This niche may aid in the maintenance and survival of leukemic stem cells while disrupting normal blood cell production and immune function.
The inflammatory microenvironment is linked to decreased effectiveness of therapies by promoting drug tolerance and altering responses to treatment.
Further understanding of specific inflammatory circuits and cytokine interactions is necessary for developing targeted combination therapies.

Simplified

Inflammation is a prominent feature of the bone marrow microenvironment in acute myeloid leukemia and contributes to leukemic evolution, progression, and therapeutic resistance. Accumulating evidence indicates that inflammatory signals in AML arise from multiple sources, including age-associated inflammaging, mutation-driven pathways, cell-intrinsic stress programs, and external inflammatory stimuli such as infections. These signals collectively facilitate the progression from clonal hematopoiesis and other pre-leukemic states to overt leukemia and support malignant expansion. Leukemic blasts, immune effector and regulatory cells, mesenchymal stromal cells, and endothelial cells collectively establish an inflammatory niche through the production of cytokines and chemokines. This niche supports leukemic stem cell maintenance and fitness, promotes metabolic adaptation and survival, and disrupts normal hematopoiesis and immune surveillance. The inflammatory microenvironment can also compromise therapeutic efficacy by inducing drug tolerance, reinforcing protective bone marrow niches, and reshaping responses to chemotherapy, targeted therapies, immunotherapies, and transplantation-associated graft-versus-leukemia effects. Although increasing mechanistic insights have inspired strategies aimed at neutralizing inflammatory mediators, blocking downstream signaling pathways, or reprogramming the microenvironment to restore anti-leukemic immunity, such anti-inflammatory approaches remain incompletely explored in clinical practice. A deeper understanding of cell type-specific inflammatory circuits and cytokine interactions will be essential for developing rational combination therapies to overcome microenvironment-driven resistance.

Full Text

Full text is available at the source.

View Full Text ↗

Inflammation as a key factor in the development and treatment resistance of acute myeloid leukemia

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief